Table S1, Figure S1,Table S2, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9 from Combining Neratinib with CDK4/6, Mtor, and MEK Inhibitors in Models of HER2-positive Cancer